Novavax announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for its Nuvaxovid XBB.1.5. to prevent Covid-19 in people aged 12 and over.

' Today's authorization by the MHRA is recognition of the role our vaccine can play in protecting the British public against Covid-19 this year,' said John C. Jacobs, President and CEO of Novavax.

The approval is based on non-clinical data showing that Novavax's updated vaccine induces functional immune responses for the XBB.1.5, XBB.1.16 and XBB.2.3 variants.

Copyright (c) 2024 CercleFinance.com. All rights reserved.